LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

LLY

902.07

-1.52%↓

JNJ

241.06

-0.02%↓

ABBV

210.65

+1.54%↑

NVS

150.35

-0.71%↓

MRK

119.42

-0.12%↓

Search

Puma Biotechnology Inc

Avatud

SektorTervishoid

6.27 -3.09

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.13

Max

6.44

Põhinäitajad

By Trading Economics

Sissetulek

3M

12M

Müük

21M

76M

P/E

Sektori keskmine

10.246

57.05

Kasumimarginaal

15.633

Töötajad

179

EBITDA

13M

27M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-20.13% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-40M

318M

Eelmine avamishind

9.36

Eelmine sulgemishind

6.27

Uudiste sentiment

By Acuity

50%

50%

167 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. märts 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Infosys Agrees to Acquire Stratus

25. märts 2026, 23:58 UTC

Tulu

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25. märts 2026, 23:58 UTC

Tulu

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25. märts 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25. märts 2026, 23:41 UTC

Tulu

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25. märts 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Declines on Possible Technical Correction -- Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25. märts 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25. märts 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25. märts 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25. märts 2026, 21:13 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. märts 2026, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

25. märts 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25. märts 2026, 20:31 UTC

Tulu

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-20.13% langus

12 kuu keskmine prognoos

Keskmine 5 USD  -20.13%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

167 / 350 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat